Use of convalescent plasma therapy in Eight mild COVID-19 patients.

The coronavirus disease 2019 (COVID-19) is still global epidemic. Several studies of severe COVID-19 patients regard convalescent plasma (CP) transfusion as an effective therapy. However, there are no significant improvements in the randomized clinical trial of CP treatment. Until now, the data of mild COVID-19 patients transfused CP were lack. This study recruited 8 mild COVID-19 patients received at least one dose of CP transfusion. After CP therapy, all patients improved the clinical symptoms. The level of lymphocyte counts tended to increase, meanwhile LDH, CK and AST tended to decrease. However, CRP of 3 patients increased transiently. The median time that SARS-CoV-2 nucleic acid of the patients turned to negative was 2.5d after CP transfusion. The study shows the potential benefits of CP. Meanwhile, CP probably enhances the inflammatory response to SARS-CoV-2 temporarily in the patients with insufficient antiviral immunity. However, the effects of CP are not permanent.